Montelukast Sodium

Verify with FDA CVM →

12 adverse event reports submitted to the FDA

Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
12
Total Reports
0
Deaths Reported
0.0%
Death Rate

Active Ingredients

Montelukast Sodium

Administration Routes

UnknownOral

Species Affected

Human 11
Dog 1

Most Affected Breeds

Unknown 11
Setter - English 1

Most Reported Reactions

Accidental exposure 5
Tingling sensation 2
Dry mouth 2
Abdominal pain 2
Nasal irritation 2
Vomiting 2
Throat irritation 1
Jaw disorder 1
Drowsiness - neurological disorder 1
Eye irritation 1
Numbness 1
Injection site bruising 1

Outcome Breakdown

Recovered/Normal
6 (50.0%)
Outcome Unknown
3 (25.0%)
Ongoing
3 (25.0%)

Data Summary

Metric Value
Total adverse event reports 12
Reports involving death 0
Case-fatality rate (reported events) 0.0%
Distinct species in reports 2
Distinct breeds in reports 2
Distinct reactions reported 20
Active ingredients on file 1

Source: FDA Center for Veterinary Medicine — Adverse Event Reporting (CVM AER). Counts reflect voluntary reports only.

Montelukast Sodium Adverse Event Insights

The FDA Center for Veterinary Medicine database currently holds 12 adverse event reports referencing Montelukast Sodium, including 0 reports in which the animal died — a 0.0% case-fatality figure among reported events only, not a population-level mortality rate. Active ingredient on file: Montelukast Sodium. Reported administration routes include Unknown, Oral. These numbers reflect voluntary submissions from pet owners, veterinarians, and manufacturers and therefore under-represent mild events and over-represent severe ones — a pattern the FDA has documented repeatedly for pharmacovigilance datasets.

The species most frequently named in Montelukast Sodium reports are Human (11 reports), Dog (1 reports), with Human accounting for the largest share. Within those species, Unknown (11), Setter - English (1) appear most often — though breed popularity and ownership density shape these counts as much as any drug-specific sensitivity. This distribution matters because the same active ingredient can behave very differently across body sizes, ages, and species physiology.

The most commonly reported clinical signs associated with Montelukast Sodium are Accidental exposure (5), Tingling sensation (2), Dry mouth (2), Abdominal pain (2). Of the 12 reports with a coded outcome, Recovered/Normal is the leading category at 50.0%. Because FDA adverse event data describes correlation rather than causation, these figures are best used to frame informed questions with a veterinarian and to compare reporting patterns across related products — not as a standalone safety verdict on Montelukast Sodium.

Source: FDA Center for Veterinary Medicine — Adverse Event Reports FDA Center for Veterinary Medicine — Adverse Event Reports Data reflects voluntary submissions and may not represent actual incidence rates

Related

Data sourced from official AKC, AVMA, ACVO, and breed-club veterinary references. See our methodology for details. Retrieved and formatted by PlainBreed Editorial